THE IRON ION-MYCOPHENOLATE MOFETIL CHELATION COMPLEX INTERACTION

铁离子-麦酚酸酯螯合络合物相互作用

• 批准号: 7376519
• 负责人: JEONG HUN PARK
• 金额: $ 0.15万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-05 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376519
• 关键词: chelating agents; ions; iron; kidney; mycophenolate mofetil

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study is being performed to assess the interaction between two medications, iron and mycophenolate mofetil, which are frequently used in kidney transplant recipients. A large portion of the transplant population, particularly renal allograft recipients, experience anemia requiring iron supplementation. In a recent research study performed in normal healthy volunteers, it was observed that mycophenolic acid levels (the marker for the drug mycophenolate mofetil in the blood) were significantly lower when taken with an iron supplement. Twenty patients representative of the stable outpatient renal transplant population will be recruited. This study is designed to determine the extent and magnitude of this interaction under several conditions: 1) when iron is taken at the same time as mycophenolate mofetil; 2) when iron is taken two hours after mycophenolate mofetil; 3) this study will also examine the effects of interaction with immediate release and sustained release iron products. The results of this study may provide information that will better direct the use of these medications in the transplant population.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。这项研究是为了评估两种药物之间的相互作用，铁和霉酚酸酯，这是经常用于肾移植受者。大部分移植人群，特别是肾移植受者，经历需要补充铁的贫血。在最近的一项在正常健康志愿者中进行的研究中，观察到麦考酚酸水平（血液中药物麦考酚酸酯的标志物）与铁补充剂一起服用时显着降低。将招募20例代表稳定门诊肾移植人群的患者。本研究旨在确定在以下几种条件下这种相互作用的程度和幅度：1）当铁与吗替麦考酚酯同时服用时; 2）当铁在吗替麦考酚酯后两小时服用时; 3）本研究还将检查与速释和缓释铁产品相互作用的影响。这项研究的结果可能提供的信息，将更好地指导这些药物在移植人群中的使用。